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Abstract: Neurodegenerative diseases (NDs) bear a lot of weight in public health. By studying
the properties of the blood-brain barrier (BBB) and its fundamental interactions with the central
nervous system (CNS), it is possible to improve the understanding of the pathological mechanisms
behind these disorders and create new and better strategies to improve bioavailability and therapeutic
efficiency, such as nanocarriers. Microfluidics is an intersectional field with many applications.
Microfluidic systems can be an invaluable tool to accurately simulate the BBB microenvironment, as
well as develop, in a reproducible manner, drug delivery systems with well-defined physicochemical
characteristics. This review provides an overview of the most recent advances on microfluidic
devices for CNS-targeted studies. Firstly, the importance of the BBB will be addressed, and different
experimental BBB models will be briefly discussed. Subsequently, microfluidic-integrated BBB models
(BBB/brain-on-a-chip) are introduced and the state of the art reviewed, with special emphasis on their
use to study NDs. Additionally, the microfluidic preparation of nanocarriers and other compounds for
CNS delivery has been covered. The last section focuses on current challenges and future perspectives
of microfluidic experimentation.
Keywords: Neurodegenerative diseases (NDs); blood-brain barrier (BBB); central nervous system
(CNS); microfluidics; organ-on-a-chip; brain-on-a-chip; brain delivery; drug delivery; nanoparticles
(NPs); nanocarriers
1. Introduction
Neurodegenerative diseases (NDs) such as Parkinson’s disease (PD), Alzheimer’s disease (AD),
Amyotrophic lateral sclerosis (ALS), Multiple sclerosis (MS) or Huntington’s disease (HD) are among
the disorders with the highest incidence worldwide, with their increase alarming when it comes to
the elderly population [1,2]. In light of their prevalence, they represent a critical public health and
economic concern [3]. These ailments are marked by different clinical features, depending on the
involved regions of the central nervous system (CNS), with some causing cognitive and memory
dysfunction, and others instigating motor impairment [4]. Several biological mechanisms contribute to
the appearance and chronic progression of NDs, including oxidative stress, mitochondrial dysfunction,
neural excitotoxicity, protein aggregation, depletion or deficient synthesis of neurotransmitters or
their degradation in the synaptic cleft due to higher enzymatic activity, and gross malfunction of the
blood-brain barrier (BBB) [5].
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The BBB is a highly complex dynamic interface between the bloodstream and the brain,
effectively protecting the CNS from potentially harmful external elements and maintaining cerebral
homeostasis [6,7]. BBB disruption, linked with increased permeability, impairment of influx/efflux
mechanisms and infiltration of toxins and immune cells in the CNS, is a common factor to many NDs [7].
The establishment of in vitro biomimetic platforms that can precisely replicate the functional/structural
properties of the BBB and enable the monitoring of changes to its integrity, could therefore enhance the
understanding of NDs, as well as accelerate the research and development of innovative therapies [6,7].
Ideally, to faithfully recapitulate the human brain endothelium, in vitro BBB models should possess
some of its essential features, including interactions between different types of cells (e.g., vascular
endothelial cells, astrocytes and pericytes), a 3D vessel-like structure of the endothelial cells, the
presence of a basement membrane and flow-induced sheer stress [6,7].
Microfluidics is an intersectional field that deals with systems that process or manipulate nanolitre
amounts of fluids, using channels ranging in size from tens to hundreds of micrometres [8]. Advances in
microfluidic technology have led to the generation of devices (so-called organs-on-a-chip) that can be
standardized at various scales and flow regimes, allowing the simulation of BBB in vivo physiology
through reconstitution of its multicellular architecture and physicochemical microenvironment [7,9,10].
Conventional 2D or 3D systems cannot produce such levels of tissue and organ functionality [10].
By providing a highly controlled cellular microenvironment, organs-on-a-chip are suitable tools
to assess the responses of the BBB to physiological and pathological stimuli, including analysis
of metabolic, genetic and biochemical activities [7,10]. Furthermore, they also allow for real-time,
high-resolution imaging [10]. Thus, these types of models have huge potential for a wide variety of
applications, including the study of NDs aetiology, biomarker identification, neurotoxicity testing or
high-throughput screening of CNS drug candidates [7,10].
Currently, none of the available medicines are able to stop or slow the continuous loss of neurons
that occurs in NDs, with therapy being majorly focused on symptomatic relief [4]. Considering that
the number of cases is expected to rise, with the World Health Organization (WHO) predicting that
in 20 years’ time NDs will become the second leading cause of death, there is an urgent and unmet
need to come up with more effective therapies [11,12]. However, the treatment of brain diseases is
severely hindered by the BBB [13]. Under normal circumstances, the BBB only allows selective passage
of molecules essential to the functioning of the brain, restricting the entrance of 98%, or more, of
therapeutics [14].
In this context, nanotechnology-based approaches such as nanoparticles (NPs) present an
opportunity to rethink and retackle the adversities connected to poor BBB permeability when delivering
drug candidates/diagnostic agents to the CNS. These targeting strategies have the potential to make
use of receptors and transporters commonly expressed at the luminal side of the brain endothelium
to transport therapeutics across the BBB, leveraging internalization mechanisms that differ from
the pathways taken by the majority of free drugs [15,16]. NPs can have significant advantages
over traditional pharmaceutical formulations, including biocompatibility and biodegradability of
their materials, ease of scaling-up, reduced toxicity, controlled and targeted delivery, enhanced
bioavailability and dissolution rate, improved pharmacokinetics and therapeutic effects, and protection
of encapsulated biomolecules [17,18].
Conventional methods of NPs preparation are sometimes associated with lack of precise control and
high batch-to-batch variations. In this area, microfluidics has emerged as a forthcoming and noteworthy
alternative, enabling fine tuning of process parameters and optimization. Microfluidic platforms
allow for better control and reproducibility over NPs properties, including size distribution, zeta
potential or ligand density, which are critical for their clinical translation as prime drug carriers [8,19,20].
Importantly, the volume of the fluids used, enables a substantial reduction in the consumption of
reagents, being cost-effective [8]. Furthermore, given that the process of formation of NPs occurs
in a continuous flow pattern, with preservation of controlled hydrodynamic conditions inside the
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microchannels, it is possible to obtain highly monodisperse nanosystems, avoiding batch-to-batch
variability [8,19].
This review provides an overview of the most recent advances in microfluidic devices
for CNS-targeted studies. Firstly, the importance of the BBB will be addressed, and different
experimental BBB models will be briefly discussed. Subsequently, microfluidic-integrated BBB models
(BBB/brain-on-a-chip) are introduced and the state of the art reviewed, with special emphasis on their
use to study NDs. Additionally, the microfluidic preparation of nanocarriers and other compounds for
CNS delivery have been covered. The last section focuses on current challenges and future perspectives
of microfluidic experimentation.
2. The Blood-Brain Barrier (BBB)
The BBB is a highly specialized capillary wall, primarily comprised of brain endothelial cells and
its basement membrane. Adherens and tight junctions (TJs) form cell–cell adhesions that maintain
the integrity of the microvasculature but severely limit the paracellular transport, thus making
transcellular diffusion the main transport mechanism of molecules between the blood and the brain,
and vice-versa [21]. Brain capillaries are encircled by astrocytic perivascular endfeet, which contribute
to the regulation of ion concentration and clearance of neurotransmitters, and by pericytes through
the basal laminal, having a crucial role in the regulation of blood flow, BBB integrity and transport.
Neurons and microglia also participate in the formation of the BBB, establishing with the astrocytes
and pericytes a dynamic functional unit, called neurovascular unit (NVU) (Figure 1). Functional
signalling and interaction between these components is the basis for BBB stability and its response to
pathophysiological stimuli [21,22].
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As a physical and biochemical barrier, the BBB has an essential role in brain homeostasis, limiting
the entry of harmful toxins and pathogens present in the blood, while supplying the fundamental
nutrients and molecules needed for normal cell function [22]. Although the restrictive nature of the
BBB is extremely important for the protection of the CNS, it poses a challenge when it comes to the
management of brain diseases, since therapeutic molecules are not able to penetrate the basement
membrane and reach the intended target site. The entry of therapeutic candidates into the brain
parenchyma depends on several factors [21]. As previously mentioned, paracellular transport is very
limited and negligible. Low molecular weight (less than 400–500 Da) lipophilic substances, preferably
neutrally charged, permeate the brain through passive transcellular diffusion [23]. It is also possible to
take advantage of some active transport mechanisms in order to assist drug penetration across the
BBB, including [22,23]:
• Carrier-mediated transcytosis (binding of a molecule to a protein carrier on the apical side of the
capillary wall, followed by its conformational change and transport of said molecule to the other
side of the membrane).
• Receptor-mediated transcytosis (binding of a particular ligand to a specific receptor, such as
transferrin or low-density lipoprotein receptors, with the formation of a ligand-receptor complex
which is carried through the cytoplasm and released on the basolateral side of the BBB).
• Adsorptive transcytosis (electrostatic interaction between positively charged molecules and the
negatively charged plasma membrane).
Despite the fact that therapeutic molecules might get access to the CNS by passive or active
transport, many are subsequently removed by efflux pumps such as the P-glycoprotein (P-gp) or
isoforms of the multidrug resistance protein (MRP), resulting in the extrusion of the drugs back
into the blood circulation and further complicating the effective treatment of brain disorders [22,24].
Hence, with the aim to optimize the therapeutic effect of the drugs, some tactics focus on evading
or inhibiting the efflux pumps [23]. An interesting aspect to consider is that, depending on the CNS
disorder, distinct expression profiles of efflux transporters are observed. For instance, in MS, there
is a decrease in endothelial cell P-gp, whereas MRP1 or MRP2 remain unchanged [25]. In turn, in
ALS, there is an increase in the P-gp but not MRP 1, 2, 4 or 5 expression in the cerebral cortex and
spinal cord [26]. This suggests that a rather complex interplay between age-related decrease and
disease-related stimulation, may lead to differences in the levels of such efflux pumps [27].
There is a recognized link concerning pathological impairment/disruption of the BBB and the
development of NDs. Several morphological alterations of cellular elements, as well as changes
at a molecular level, lead to BBB breakdown, with ensuing neural inflammation, dysfunction and
degeneration. Numerous factors may be involved in the BBB disruption, including reactive oxygen
species (ROS), angiogenic factors, inflammatory cytokines, mitochondrial dysfunction, aberrant
intracellular signalling, autoantibodies, leukocyte adhesion and pathogens [28]. Degenerative changes
in the microvasculature persist as the disease evolves, and may be reflected in reduced expression of
TJs or adherens junctions, defective expression or function of transporters, upregulation of luminal
adhesion molecules, astrocyte loss, pericyte detachment, insufficient clearance function or disrupted
basement membrane [28–30]. The implications vary from unregulated molecular and ionic fluxes,
extravasation of plasma proteins, entry of pathogens and toxins, to the onset of a central inflammatory
response with microglial and astroglial activation, as well as release of cytokines and chemokines [28,31].
However, it can be said that the single most important outcome is that the integrity of the BBB is
severely compromised, mainly manifesting as increased barrier permeability [28].
In recent years, exponential focus has been given to alterations of the extracellular matrix (ECM)
of the basement membrane as a key contributor to the pathological process of NDs. For instance, it
has been shown that matrix metalloproteinases (MMPs), in cases of chronic neurodegeneration, drive
forth the progression of symptomatology in AD and PD [32]. Increasing evidence also indicates that
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dysbiosis of gut microbiome may influence and contribute to the onset and progression of a number of
diseases, including NDs [33].
Overall, it is critical to have a better understanding and translation of the BBB physiological and
pathological processes that precede and increase vulnerability to NDs, since it might offer new avenues
to help identify novel strategies and therapeutic targets for drug discovery and development.
3. Experimental BBB Models
3.1. In Vivo Models
BBB research is met with challenging difficulties given its complexities and relative inaccessibility.
Reconstituting critical features of the BBB, as well as of NDs, is imperative not only to improve
the understanding of the mechanisms behind these incurable disorders, but also to accelerate drug
discovery [32].
Currently, there is a heavy reliance on animal models to study in vivo cell behaviour. They are
regarded as the gold standard, since they closely mimic the complexity of the BBB microenvironment
and the individual diversity found in humans [34,35]. Nevertheless, it is necessary to consider the
occurrence of species-specific biological differences, and thus, ultimately, their inadequate reproduction
of human pathophysiology [32]. Given the existence of immunological, genetic and cellular variances
between humans and animals, no in vivo model is capable of faithfully recapitulate all aspects of human
brain disease [36,37]. This is an important disadvantage, since it becomes problematic to translate
the results obtained using animals to the human context. Indeed, more than 80% of compounds that
were successfully tested in animal models failed in clinical trials [37]. Poor experimental methodology
and species-to-species variability in protein expression profiles may also contribute to explain this
issue [35]. Furthermore, it is believed that most NDs are polygenetic, comprising multiple, and
frequently unrecognized, genetic alterations, which makes the generation of transgenic animals very
challenging [38]. Other critical drawbacks of using animal models include ethical concerns, elevated
costs and prolonged, low-throughput, labour-intensive processing [39]. The global implementation
of the 3Rs principles (reduction, refinement and replacement) also underlines the requirement to
abandon animal testing as much as possible in the future, rerouting even more the investigation of
NDs pathology to in vitro models [32].
3.2. In Vitro Models
To circumvent the issues regarding the use of animals, scientists commonly resort to
two-dimensional (2D) and three-dimensional (3D) in vitro models as an alternative (Figure 2) [34].
Cell culture technology is fairly straightforward and can be performed in carefully monitored conditions,
thus making it relatively robust and with good reproducibility [34,37]. Additionally, it is generally
cheaper to acquire and maintain when compared to animal models [34]. There are different models
available, namely, 2D or 3D static cell cultures, and 2D or 3D perfusion microfluidic systems [40].
Starting with 2D static cell cultures, they are a staple for many applications like toxicity or
metabolism analysis [38,41]. These systems are well known, with extensive literature allowing to
critically analyse the data obtained, and understand the cell behaviour in many conditions [40]. In the
most basic 2D models, cells are attached to a medium-containing flat surface such as flasks, dishes
or well plates, where they are able to adhere and spread [32,42]. To enable BBB drug transportation
studies, the Transwell® setup was created, with one or more types of BBB cells being cultured on
semi-permeable microporous inserts [35,37]. Transwell® systems are widely utilized, since they are
user friendly and cost-effective, increasing test speed and cutting down reagent consumption [37].
Cells of human origin can be used, therefore sidestepping problems with translation of results to
the clinic.
However, even when co-culture is done, 2D cell cultures have significant shortcomings.
The production yield is low, and cell growth occurs unnaturally in reaction to external factors [42].
Pharmaceutics 2020, 12, 542 6 of 37
More importantly, there is a failure to properly replicate and reproduce key aspects of the BBB
microenvironment, including cell–cell and cell–ECM interactions that occur within the NVU [34,41].
In addition, they are restricted in supplying suitable electrical, mechanical and chemical cues, which
can lead to subtle differences in barrier permeability and cell morphology when compared to in vivo
models [41]. Even though the realism of 2D cultures can be somewhat improved by incorporating more
cell types or by using human cells, robustness is sacrificed, and thus, these models are not appropriate
when the intention is to model higher order features and trajectories of the CNS [38].
3D cell systems have garnered attention for decades, being introduced as an attempt to better
represent the intricate human physiology and relevant conditions, therefore allowing to improve the
simulation of the in vivo setting of cells inside organs and tissues [32,41]. Traditional 3D cultures
are usually achieved by culturing cells on biocompatible extracellular scaffolds (such as hydrogels),
either in well plates or on Transwell® membranes [32,34]. By using hydrogels that incorporate
natural molecules of the ECM (e.g., collagen or fibrin) or synthetic polymers (e.g., polylactic acid
(PLA) or polyglycolic acid (PGA)), cells are induced to polarize and interact with neighbouring
cells, randomly interspersing in the ECM or self-assembling into physiological-like microstructures
(organoids) [32,34,43]. Furthermore, culture systems can also self-organize in 3D aggregates in a
scaffold-free manner, without the need of a supportive matrix, giving rise to spheroids [44].
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Nonetheless, 3D cell cultures also have their own drawbacks. Firstly, some of these models are
not high-throughput or cost-effective, and often, there are problems regarding the existing protocols
not being reproducible [32]. The macroscale of 3D leads to challenges in the transportation of nutrients
and oxygen, as well as in cell viability, analysis, sampling and imaging, as its complexity increases [41].
Although 3D in vitro cultures are b tter at emulating certain aspects of the spatial complexity of the
CNS and of the BBB microenvironment (including molecular and signalling pathways), many systems
still lack the level of multiscale architecture and tissue-tissue interfaces that influence the function and
development of organs in both health and disease, including the brain: for instance, just like it happens
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with 2D models, cells in traditional static 3D models are not exposed to dynamic stresses like fluid
flow from pressure gradients, or tension and compression. Moreover, they also fail to take into account
biochemical effects that are specific to each cell type within a co-culture, when trying to reconstitute
the NVU [10,32].
Recently, progresses in microfabrication techniques have allowed to the integration of cell/tissue
engineering on microfluidic platforms, leading to the development of a new, revolutionary type of
model: organ-on-a-chip. Organs-on-a-chip combine the advantages of in vivo and traditional in vitro
models, while potentially overcoming most of their limitations [35,41]. In this sense, in the next sections
we will discuss the value and the state-of-art of this highly promising approach to mimic BBB/brain
physiology and function, as well as for studying NDs pathology.
4. Microfluidic BBB In Vitro Models (BBB/Brain-on-a-Chip)
The rise in microscale technologies has opened avenues for the development of more complex
and advanced CNS biological models that are unachievable with conventional cell culture systems [39].
Organs-on-a-chip are microfluidic devices for culturing cells in continuously perfused, micrometre-sized
chambers, engineered in such a way to enable them to closely mimic and better replicate the dynamic
conditions, and the in vivo microstructure/environment of a tissue or organ (in this case, of the human
BBB or brain) [10,35,45]. The goal is not to build a whole living organ but rather to synthesize minimal
functional units that recapitulate tissue- and organ-level functions, thus allowing the development of a
BBB model on a microdevice in order to study physiological and pathological phenomena [10,32,45].
Early research focused on simpler systems, consisting of a single microfluidic chamber containing one
kind of cultured cell [46]. As knowledge advanced, more complex designs were created, generally
entailing multiple microchambers connected with microchannels or microgroove arrays, and cultured
with distinctive cell types to reproduce interfaces among different tissues (e.g., the BBB) [10,46].
Microfluidics-based models have the ability to regulate primary factors like cell patterning,
cell–cell and cell–ECM interactions or transcellular oxygen, molecular and chemical gradients, as
well as to provide physiologically relevant levels of fluid flow shear stress and cyclical mechanical
forces analogous to those seen in blood vessels (i.e., perfusion culture) [10,41,46]. Accurate control
of fluid flow is very useful, since it improves the function, differentiation and long-term survival of
many cell types [10]. Such interactions and clear interplay between microenvironmental elements
and culture parameters are not achievable with traditional cell systems [47]. Moreover, microfluidic
approaches offer a plethora of other advantages that make them a unique platform to replace or at
least complement other models for high-throughput drug screening and disease modelling, such as:
(1) Being highly customizable and having better experimental flexibility and control (such as in-chip
design or in vitro biochemical and mechanical microenvironment conditions), thus giving reply
to specific requirements of each experiment and cellular system [32,39,47].
(2) Significant reduction in chemical cost and consumption, since far less minute amounts of cells,
culture medium and other reagents are needed [41,47].
(3) Continuous supply of nutrients and waste removal [40].
(4) Schedule flexibility [40].
(5) Reduced risk of contamination [47].
(6) Possibility of multifunctional integration of analytical biosensors and other electronic apparatus
(e.g., microscopy devices, microelectrode arrays (MEAs), etc.) for real-time/on-chip or downstream
monitorization of cellular behaviour, detection of physiological parameters (e.g., biomarkers
or chemokines levels) and in situ analysis of external stimuli, therefore decreasing analysis
time [32,40,46,47].
(7) High automation capability [47].
(8) Possibility of single-cell handling, compartmentalized culture, co-culture and long-term
culture [39,47].
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(9) Possibility to test in the same controlled environment both healthy and disease tissues [35].
The real value of microfluidics is their ability to independently vary many of the previously stated
control parameters, while carrying out real-time, high-resolution imaging of the events at a molecular
scale in the tissue or organ studied [10]. It is not surprising that the implementation of microplatforms
has gained traction, being progressively employed in BBB studies, since they can closely simulate the
in vivo microenvironment of the CNS, while using different types of cells (including neurons, glial
cells or even brain tissues) [39]. Microfluidic systems replicate organ-level functions, being therefore
better suited when compared with conventional in vitro models for higher level studying of biological
interactions and response to stimuli within the BBB, cellular activities/mechanisms that play a key role
in NDs pathology or even evaluation of CNS drugs [35,37,40].
Different manufacturing processes are available to control the surface topology, and construct
organs-on-a-chip: photolithography, soft lithography, embossing, moulding, etching, 3D printing, laser
ablation and so forth [38,39,47,48]. Appropriate selection of chip material is pivotal, since it can not only
improve sensitivity, accuracy and stability, but also reduce experimental costs [37]. The most prevalently
used material is polydimethylsiloxane (PDMS). PDMS is a biocompatible polymeric compound, which
is reasonably inexpensive and can be applied in such a way to meet specific experimental requirements.
It is robust and non-toxic, gas, vapour and water-permeable, and optically transparent, all important
and convenient features for cell culturing in microfluidic chips. Furthermore, the fabrication and
set-up of PDMS-based systems is relatively straightforward, with mass production of chips from
one mould being easily attainable, which is especially advantageous in academia/university settings.
However, PDMS devices have some limitations for BBB studies, such as incompatibility with most
organic solvents or poor affinity for adhesion of living cells, given their hydrophobic nature. Moreover,
their softness and elasticity make them less than ideal for industrial scale production. To overcome
these constraints, thermoplastics (e.g., poly(methyl methacrylate), polystyrene, cyclic olefin copolymer)
can be employed instead [37,48].
As indicated earlier, microfluidic systems can assume a 2D or 3D configuration [40].
Notwithstanding the design or configuration, when implementing a new microfluidic model it
is always essential to evaluate that model’s performance [37]. This typically involves assessing barrier
integrity and tightness by measuring transepithelial electric resistance (TEER) values, testing for
the presence of specific BBB markers of TJs (e.g., zona occludens-1, claudin-5, P-gp) and observing
the permeability of model compounds (e.g., fluorescein isothiocyanate (FITC) labelled dextrans or
D-mannitol) [37].
Still, hurdles arise when trying to establish a culture on microfluidic devices [49]. Each key
component of a BBB- or brain-on-a-chip (manufacturing method, chip material or design, culture
biomaterials, cues and biosensors) can present specific technical challenges [48]. Manufacturing of
these devices requires specialized micro-engineering skills [10]. The diversity of device designs, the
lack of standardized culture protocols and of quantification of BBB parameters, the variety of cell
lines, as well as the cell-specific responses/behaviour to microfluidic culture, make generalizations and
comparison between platforms difficult [35,49]. Indeed, different cell types respond contrastingly when
moved from macroscopic to microfluidic culture [49]. Furthermore, operational control is complex [49]:
to achieve a consistent and robust cell seeding in the microchambers is tricky, as well as to precisely
control the cell–cell and cell–ECM interactions necessary to generate exact tissue structure-function
relationships [10]. The use of thin ECM coating or simplified ECM gels can lead to contraction or
degradation of the matrix over time, which is obviously problematic for long-term cell survival,
despite continuous perfusion. Occurrence of bubbles within the microchannels is another issue.
Their complete removal can be difficult, potentially leading to cell damage [10]. Finally, satisfactory
intra- and inter-batch reproducibility of the same organ-on-a-chip still needs to be achieved [48].
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4.1. 2D Microfluidic Systems
Recently, Jeong et al. [50] devised a PDMS bilayer chip design wherein neural endothelial cells and
astrocytes were co-cultured in a polycarbonate membrane. With this configuration, the endothelial cells
and astrocytes are physically separated and grow in two separate microenvironments, being allowed
however to establish localized interactions through the pores of the membrane, which is important
for the development of a realistic brain-capillary interface. The cross-section of the 4 microchannel
rows and columns that comprise the luminal and abluminal PDMS layers (intending to represent the
blood and brain side, respectively), resulted in an array of 16 semi-independent BBB testing areas
on a single chip. Each of the 16 BBB testing areas was fitted with integrated electrical sensors to
analyse non-invasively and continuously the TEER values. Barrier function was additionally confirmed
using two other methods, namely, immunofluorescent staining and molecular permeability assays.
Immunostaining revealed that there was a time-dependent formation of TJs, since the expression of
ZO-1 (a TJ protein) increased accordingly with the division of endothelial cells. Moreover, the authors
demonstrated that the ZO-1 expression level is also affected by ECM composition and sheer stress.
Regarding ECM selection, coating the membrane with Matrigel® generated higher TEER values over
time (615 ± 122 Ω at day 0 to 3368 ± 441 Ω at day 4) when compared to fibronectin coating, which
correlates to the time-dependent increases in ZO-1 expression, and justifies the use of this material in
subsequent experiments. Higher levels of sheer stress led to increased number of TJs, but when too
high (30 dyn/cm2), ZO-1 expression actually decreased. Therefore, an optimized level of 20 dyn/cm2
was used, falling under the range of reported in vivo levels (5–25 dyn/cm2). Dextran permeability
assays showed co-culture conditions have a permeability coefficient almost 2.5-fold lower compared to
a monoculture of endothelial cells only, reinforcing the notion that the interactions between endothelial
cells and astrocytes are essential for the formation of a tighter BBB barrier. Furthermore, the triple
co-culture chip provided preliminary evidence of a closer, more faithful drug testing capability to the
one that happens in in vivo BBB, since even after treatment with histamine (a known TJs disruptor),
almost no change in the TEER values was detected, whereas for the monoculture BBB chip, there was a
drop in the TEER values, which indicates an increase in permeability [50].
Griep et al. [51] further demonstrated that fluidic forces affect the integrity of the BBB. They showed
that applying a physiologically relevant shear stress (5.8 dyn/cm2) on a small BBB-on-a-chip, composed
of a monolayer of a human cerebral microvascular endothelial cell line (hCMEC/D3) cultured in a
membrane coated with collagen I and two layered PDMS chamber, results in an increased expression
level of TJ proteins, improving endothelial cell function and inducing a significantly higher barrier
tightness. This resulted in a 3-fold increase of the average TEER value from 37Ω·cm2 (static conditions)
up to 120 Ω·cm2, measured with integrated platinum electrodes. Moreover, barrier function is also
biochemically modulated, since stimulation with inflammatory protein tumour necrosis factor α
(TNF-α) negatively impacted the TEER, leading to a 10-fold decrease, down to 12 Ω.cm2. The use of a
single device to compare both static and dynamic TEER values is advantageous, given that it avoids
possible experimental variability [51].
Achyuta et al. [52] made a modular device to recreate in vitro the NVU (Figure 3a). The device
consisted of two PDMS parts—a vascular conduit overlaid on top of a neural chamber—, separated
by a polycarbonate membrane. The vascular chamber was coated with bovine plasma fibronectin,
and rat brain endothelial cells (RBE4 cell line) were cultured in this channel for 2 days under static
conditions. In its turn, the neural part was coated with poly-D-lysine and cultured with E-18 rat cortical
cells for 10 days, which differentiated into a mixture of astrocytes (95%), neurons (4%) and microglia
(1%), in the presence of serum and basic fibroblast growth factor (b-FGF). Since brain endothelial and
neuron–glial cells have different maturation periods, they were cultured separately, and afterwards,
both chambers were assembled, in order to allow communication via the membrane. Functional assays
were conducted. Both E-18 and RBE4 cells showed good viability (>90%) upon live/dead staining.
Immunofluorescence revealed the presence of different markers such as von Willebrand factor (vWF),
glial fibrillary acid protein (GFAP), microtubule-associated protein 2 (MAP-2) or OX-2, indicating proper
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neural and vascular cell differentiation. Furthermore, western blot showed the presence of TJ protein
ZO-1. The integrity and tightness of the barrier was assessed with AlexafluorTM-conjugated dextran
leakage, perfused during 1h through the vascular chamber at the rate of 1 mL/h. The models containing
a RBE4 cell layer presented significantly decreased leakage into the neural reservoir compared to
devices without cells. Conversely, when the vascular layer was exposed to TNF-α for 6h, more dye
was leaked, indicating a pro-inflammatory reaction that disrupted barrier function and triggered BBB
hyperpermeability. Moreover, the circulation of the inflammatory stimulus, triggered the activation of
75% of astrocytes and microglia in the neural chamber, mimicking neuroinflammation. Several caveats
of the current model were pointed out by the authors, including the use of embryonic stem cells that
do not reproduce all the features of mature in vivo NVU, the absence of pericytes and shear stress,
or the rodent-provenience of the cells, which might make direct correlation with data from human
clinical trials impossible. However, if needed, perfusion could be applied via the vascular channel, in
order to mimic in vivo settings. In addition, control over each module also allows the user to easily
manipulate cellular seeding and cellular:neuroglial ratios, to provide other physiological cues that
impact the NVU and to observe sub-cellular features through high-content analysis. The system could
be an opportunity to deliver nutrients, drugs, cells or nanomaterials, and evaluate their impact on the
NVU [52].
In a 2017 study, Wang et al. [53] developed a 2D pumpless BBB microfluidic model (Figure 3b).
BBB constructs were prepared by co-culturing, up to 10 days, brain microvascular endothelial cells
(BMECs) (derived from human-induced pluripotent stem cells (iPSC)) with rat primary astrocytes,
on two sides of a collagen IV and fibronectin-coated porous insert. The final assembled device was
achieved by accommodating the insert between a bottom layer with microchannels (perfusion layer)
and a middle layer containing a central neuronal chamber and reservoirs filled with culture medium.
Recirculation was assured without the need of using tubing and pumps, by means of a rocking platform
that changes the tilting direction. In order to properly mimic and match tissue volume and blood
residence time of a human adult brain, the neuronal chamber and perfusion flow rate were scaled down
proportionally (residence-time based design). Furthermore, to minimize oscillatory fluidic shear stress
on the cell surface, a “step chamber” was introduced, increasing the distance between the cell plane
and the perfusion layer. This modification enabled the BMECs to survive and maintain their unique
BBB phenotype, while still providing physiologically relevant flow rates [53]. A TEER measuring probe
with costum Ag/AgCl electrodes was integrated into the microfluidic device, facilitating the monitoring
of the values and the optimization of culture conditions. This was the first microfluidic model to
achieve sustained high TEER values (above 2000 Ω·cm2 for up to 10 days) that fall within the range
of those recorded in vivo (1500–8000 Ω·cm2), being also the highest reported for any BBB-on-a-chip
system (peak TEER above 4000 Ω·cm2). Likewise, evaluation of permeability coefficients for several
large tracer molecules (4, 20 and 70 kDa FITC-dextran) and small drugs (caffeine, cimetidine and
doxorubicin), strongly correlated with in vivo BBB transport data. Doxorubicin disrupted the BBB
integrity after 24h treatment. The authors denote the convenience and simplicity of their setup, also
indicating that since it closely mimicked BBB barrier functions, the potential and suitability of this
approach for brain drug screening studies was validated. A possible improvement would be to
incorporate astrocytes of human origin instead of rat, in order to create a fully human BBB model [53].
Walter et al. [54] recreated the BBB on a biochip that consisted of a polyethylene terephthalate
(PET) membrane, situated between two PDMS channels fixated with a silicone sealant. This core was
placed between glass slides with gold electrodes. Moreover, attached to the top glass slide, there were
two PDMS blocks with reservoirs holding culture medium. The upper PDMS channel was defined
as the “blood side” and coated with collagen I, while the lower channel, representing the brain, was
coated with collagen IV. The presence of collagen, a natural element of the ECM, facilitates the seeding
of cells. This versatile microdevice enabled the formation of two different BBB models: hCMEC/D3
human brain endothelial cell line and triple co-culture of primary rat brain endothelial cells with
primary astrocytes and brain pericytes. The endothelial cells were cultured on the top side of the PET
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membrane in the top channel, while pericytes and astrocytes were cultured on the bottom channel.
For 3 days, the cells were grown under static conditions, after which a peristaltic pump provided
dynamic culture conditions at low shear stress. Characterization of cell culture was done by assessing
its morphology, TEER values and apparent permeability. As expected, the results demonstrated that
the primary rat triple co-culture was more efficient in the induction of barrier properties: it exhibited
higher TEER values (114 ± 37.5Ω·cm2 for both static and dynamic culture conditions vs. 19 ± 2.8Ω·cm2
and 28.5 ± 7.2 Ω·cm2 for the hCMEC/D3 under static and dynamic conditions, respectively) and lower
tracer permeability coefficients, indicating a tight barrier. Furthermore, immunostaining and confocal
microscopy confirmed a stronger expression of both β-catenin (adherens junction protein) and ZO-1
(TJs protein) for those cells [54].
Likewise, a multi-layered BBB microfluidic model, composed of a triple culture of co-immortalized
mouse brain endothelial cells (bEnd.3), mouse astrocytes (C8D1A) and pericytes, seeded on a 0.4 µm
micropore membrane fabricated using soft litography, was developed (Figure 3c) [55]. The membrane
was integrated between two partially overlapping PDMS microchannels, embedded with Ag/AgCl
electrodes. The top channel was connected to a pump that provided the culture medium, exposing
the endothelial cells to a fluidic shear stress of 1.6 dyn/cm2. A live/dead cytotoxicity assay proved a
high viability of all cells up to 21 days, which was further confirmed by fluorescent images of their
morphology. Interestingly, it was shown that cell alignment is influenced by the microchannel’s size
and shape, since the spindle of the cells gradually decreased along the longitudinal axis of the channel
as a function of days in culture. Compared to a single bEnd.3 monolayer and a double endothelial
cells-pericytes co-culture, the triple model had enhanced functional expression and activity of P-gp,
given that the basolateral-to-apical permeability and the efflux ratio of dexamethasone (a substrate
for P-gp) were superior, gradually increasing with the increase in culture time, thus underlying the
functionality of the efflux pump in the endothelial cells. Furthermore, it showed higher TEER values.
It is known that soluble factors such as TGFβ, bFGF or GDNF, secreted by astrocytes and pericytes, can
have a positive effect in reinforcing the integrity and barrier properties of the BBB model. The authors
demonstrated that increasing the height of the lower channel from 200 µm to 600 µm and 1000 µm,
translated in a progressive decrease of the TEER values. As channel height increases, so does the
medium volume, resulting in a dilution of those factors and, therefore, in a reduced restrictiveness of
the formed barrier. Permeability screening assays with [14C]-urea and [14C]-mannitol showed that
both the bi- and triple co-cultures have size selectivity, being able to discriminate between the two
different markers. Moreover, permeability of [14C]-mannitol after 18 days in the triple culture was
similar to its reported permeability across the BBB in vivo [55].
Yeon et al. [56] designed a BBB microfluidic model comprised of a PDMS chip with two channels,
connected by microholes (Figure 3d). Pressure gradients generated by applying different flow rates
in the microchannels, led to hydrodynamic entrapment of human umbilical cord endothelial cells
(HUVECs) in the microholes. Within 2h of incubation with astrocyte-conditioned medium (ACM),
a barrier was formed, and the permeability of various FICT-tracer dextrans (4, 40, 70 kDa) and
drugs (antipyrine, carbamazepine, atenolol, verapamil and propranolol) through the HUVEC layer
was evaluated by fluorescence microscopy and high-performance liquid chromatography (HPLC),
respectively. Compared with the untreated control, supplementation with ACM significantly decreased
the permeability of the dextran dyes, as well as of carbamazepine, verapamil, antipyrine and
atenolol, which is in good agreement with the enhanced expression of ZO-1 TJ protein detected by
immunofluorescent staining. In the case of propranolol, the difference in permeability was negligible.
Moreover, these values highly correlate with the results measured in conventional Transwell® systems,
as well as with in vivo permeability data, validating the reliability of this model to predict the
penetrability of new CNS-targeted molecules. The authors also confirmed that exposure to hydrogen
peroxide, an inductor of ROS formation, contributed to ZO-1 redistribution to the cytosol, therefore
increasing BBB permeability. Two of the main concerns of this device are that it lacks cell–cell contact,
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a fundamental characteristic of the BBB in vivo, and it does not reproduce the in vivo dimensions of
microvasculature [56].
As it is perceptible from the studies described so far in this section, one of the many applications
of microfluidic platforms is the assessment of the permeability of different compounds, facilitating the
early screening of brain-targeted drug candidates [7,37]. This is not only applicable to conventional
dosage forms, but also to novel biopharmaceuticals and nanomedicines [7]. In regard to this last
category, Papademetriou et al. [57] carried on a study wherein the objective was to evaluate the
impact of static and flow conditions on the BBB binding and internalization of angiopep-2 coupled
liposomes. The microfluidic device consisted of two S-shaped PDMS microchannels, with the region
of overlap being separated by a polycarbonate membrane treated with a mixture of fibronectin and
collagen IV, wherein mouse brain endothelial cells (b.End3) were cultured in the upper part over
3–6 days prior to experiments. The liposomes (mixture of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy(polyethylene glycol)-2000
(DSPE-PEG2k) and DSPE-PEG maleimide, MW 3400 (DSPE-PEG-MAL3.4k)) were prepared by lipid
film hydration method [58], followed by angiopep-2 conjugation. Angiopep-2 (ang-2) is a peptide of
the LPR1 transferrin receptor, facilitating brain transport and penetration. The formation of a functional
barrier was confirmed by dextran permeability size selectivity assays, as well as the measured TEER
value (172 Ω·cm2), which is far superior to baseline values already reported for BBB microfluidic
models using bEnd.3 cells (30–50 Ω·cm2). Results from fluorescence microscopy and spectroscopy
allowed to withdraw two main conclusions: firstly, that the process of functionalization resulted in
significant binding to bEnd.3 cells compared to non-functionalized liposomes, and secondly, the ang-2
nanocarriers were less internalized by the endothelial cells via receptor-mediated transcytosis under
high shear stress (6 dyn/cm2) relative to low flow shear stress (1 dyn/cm2) or in static conditions.
This suggests luminal fluid flow impacts the binding levels, and that at higher flow shear stress,
detachment forces resulting from the flow are enough to overcome the avidity of ang-2 liposomes,
uncoupling them from the endothelial cells. The claudin-5 perinuclear expression hints that flow
exposure might have partially disassembled TJs, which may have influenced the penetration of NPs
through the model. Since physiological flow shear stress in brain capillaries ranges from 5–23 dyn/cm2,
which is important to replicate, tuning the NPs characteristics (e.g., ang2 valency) might help to solve
this problem by enabling binding in the presence of flow while maximizing the BBB penetration.
As mentioned by the authors, one limitation of this study was the lack of co-culture with other cell
types that form the NVU [57]. In addition, Park et al. [59] characterized the transcellular transport
of angiopep-2 quantum dot NPs and monoclonal antibodies directed against the transferrin receptor.
The results of this study suggest that hypoxia is needed to better recapitulate the native BBB in terms of
transferrin receptor function, as well as of other BBB transporters, since when compared to normoxic
conditions, hypoxic conditions resulted in enhanced differentiation and increased expression of those
proteins [59].
In similar fashion, the effectiveness of a gH625 (a membranotropic peptide) to direct the transport
of polystyrene NPs across a BBB layer under flow conditions that mimic circulation, was tested in a
microfluidic device devised by Falanga et al. [60]. Its design was based on the thermoplastic polymer
poly(methyl methacrylate) (PMMA), which has the advantage of being easily micromachinned by
micromilling. Confocal microscopy and phase contrast demonstrated the formation of a confluent
bEnd.3 layer on a porous membrane, at 7 days of culture. Crossing experiments proved that
functionalization with gH625 peptide enhanced the adhesion of the NPs to the BBB layer, and at a
working medium flow rate of 5 µL/min, increased 2-fold the transport of NPs (6.13% compared to
2.72% of non-functionalized blank NPs). Furthermore, TEER analysis confirmed the maintenance of
barrier function before and after the passage of the nanocarriers, proving that the bEnd.3 layer is not
disrupted by the NPs. In summary, the system allowed the reproducibility of experiments and the
quantification of NPs transport across the BBB in vitro [60].
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Figure 3. Examples of 2D BBB microfluidic models: (a) modular polydimethylsiloxane (PDMS) device
to recreate the NVU by co-culture of neuroglial and endothelial cells, (b) pumpless microdevice
that provides in vivo-like BBB properties for drug permeability screening, (c) multi-layered system
composed of a triple culture of co-immortalized mouse brain endothelial cells (bEnd.3), mouse astrocytes
(C8D1A) and pericytes, (d) microfluidic device that mimics the cerebral vasculature and is a reliable
permeability assay system. Reprinted and adapted with permission from: (a) Achyuta et al. [52],
(b) Wang et al. [53], (c) Wang et al. [55]. Copyright (2016) American Chemical Society, (d) Yeon et al. [56].
Prabhakarpandian et al. [61] introduced a synthetic microvasculature model of the BBB
(SyM-BBB). The device consisted of a circular PDMS chip with microchannels, partitioned in a
two-compartment chamber: an outer ring (blood compartment—apical side) and an inner ring (brain
compartment—basolateral side), which were separated by an array of micropillars with 3 µm gaps
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between them. These gaps allowed communication between the chambers. The outer ring was
coated with fibronectin, and RBE4 rat endothelial cells were cultured under fluidic shear conditions
(0.1 µL/min) for 24-48h. ACM was added to the brain compartment, and its influence on barrier
permeability, tight junction formation and P-gp expression/activity was studied. Compared to a
conventional Transwell® and a device without ACM, the ACM-perfused model improved the overall
BBB function. It had decreased barrier permeability (reflected by lower FITC-dextran intensity levels
in the basolateral chamber), promoted expression of TJ proteins (ZO-1 and claudin) and P-gp, and
increased efflux pump activity (translated in a significantly higher efflux of Rhodamine 123, even in
the presence of verapamil, an inhibitor of P-gp). One thing that differentiates this model from the other
two-chamber assays that were described earlier is that it does not use a membrane or a filter, with the
apical and basolateral compartments being side-by-side, which simplifies fabrication. Furthermore,
its design allows the simultaneous, real-time monitoring of both compartments, provides realistic
microvasculature environment and dimensions, delivers physiological shear stress/fluid flow and
allows long-term cell culture [61].
4.2. 3D Microfluidic Systems
Marino et al. [62] resorted to a two-photon lithography technique (3D printing) to fabricate a
3D microtubular porous structure that replicates the microcapillaries of the NVU. The core benefit of
this technique is that capillary diameter, pore size or pore density are easily fine-tuned. The structure
consisted of 50 parallel microtubes with pores on the surface to allow transport toward the external
environment, connected to an inlet and an outlet reservoir. The microtubes served as scaffolds for the
co-culture of murine brain-derived endothelial cells (bEnd.3) and U87 glioblastoma line, allowing
the cells to maintain their morphology and phenotype, since it mimics the basement membrane of
the BBB. Culture medium was pumped at 50 µL/h, making the flow rate within each microtube of
1 µL/h, a value comparable to that of cerebral microcapillaries. The novelty of this work is that the
platform was constructed according to the actual dimensions of human brain capillaries, leading to the
first-time development of a real scale, biohybrid and biomimetic BBB model that showed an efficient
maturation of TJs (high expression of ZO-1 by immunofluorescence staining), decreased dextran
transcytosis and higher TEER value (75 ± 2 Ω cm2), with respect to the same microfluidic system
without cells. Even after 5 days, TEER value remained stable (71 ± 10 Ω cm2), denoting preserved cell
viability and functionality. The investigators pointed out that this model could potentially be used for
high-throughput screening of drugs or nanomaterials for several brain pathologies [62].
Wevers et al. [63] established a perfused parallel BBB-on-a-chip model, comprised of a two- or
three-lane microfluidic platform that harbours 96 or 40 chips, respectively, in a 384 well plate format
(referred to as OrganoPlate). In each chip, a microvessel of brain endothelial cells (TY10 cell line) was
formed and grown against an ECM gel composed of collagen-I. On the other side of the gel, astrocytes
(hAst human cells) and pericytes (hBPCT human cells) were added, in order to complete the model. By
placing the plate on a rocker and infusing it with medium culture on the microvessel channel, perfusion
was generated, creating a bidirectional flow from inlet to outlet and vice-versa. Expression and
interendothelial localization of key BBB TJs (claudin-5) and adherens junction (VE-cadherin, PECAM-1)
proteins was detected by immunostaining, indicating barrier formation. Moreover, barrier integrity
was assessed at days 5, 7 and 9 by a fluorescent permeability assay. The results showed that the model
was able to severely restrict the passage of a 20 kDa FICT-dextran dye, which is revealing of a functional
BBB. To study BBB diffusion by receptor-mediated transcytosis of a therapeutic antibody (antibody to
human transferrin receptor (MEM-189)), the authors infused the microvessel channel with MEM-189 or
a control antibody, quantifying afterwards its levels in the basal chamber. The penetration of MEM-189
was approximately 2-fold higher than the penetration of the control antibody (apparent permeability of
2.9× 10−5 versus 1.6× 10−5 cm/min, respectively), denoting that the binding of the therapeutic antibody
to the transferrin receptor expressed in the endothelial cells facilitates the transportation across the
BBB. All in all, the Organoplate has several advantages such as minimal absorption, low-level passive
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permeability and ease of sampling, that make it a valuable and suitable model for high-throughput
drug screening (including of large molecules like antibodies) under physiological conditions without
the need of artificial membranes [63].
Maoz and colleagues [64] recently constructed an innovative and sophisticated platform of three
interconnected microfluidic systems (Figure 4a). The modular structure comprised a brain chip put
between two BBB chips, thus recapitulating at the same time the brain parenchyma and the influx/efflux
across the BBB. The brain chip contained human neural stem cells (~60% glial cells and 40% of
dopaminergic, glutamatergic, serotonergic and GABAergic neurons) and astrocytes cultured on the
laminin and poly-l-lysine-coated surface of the lower compartment, whereas the BBB chips entailed a
monolayer of primary human brain microvascular endothelial cells (hBMVECs) at the vascular (lower)
chamber and astrocytes and pericytes at the perivascular (upper) chamber, to mimic the external wall
of a brain microvessel. To achieve successive influx and efflux from one chip to the other, and to
allow diffusion-mediated molecular transport to dominate (as what happens in vivo in the brain), the
shear stress was adjusted to be close to 0 within the brain compartment. The results of proteomic
analysis demonstrated that fluidic coupling modulates the phenotype of the cultured cells via paracrine
signalling, with more effective expression of some proteins (e.g., metabolism-associated proteins) in the
coupled chips compared to uncoupled cultures. Furthermore, the linked system allowed to compare
the individual roles of the different endothelial, neuronal and perivascular cell populations in the NVU,
obtaining insights into previously unknown metabolic interactions between them that are significant
for the maintenance of brain function. Of relevance, these metabolic interactions led to an enhancement
of the synthesis and secretion of neurotransmitters gamma aminobutyric acid (GABA) and glutamate,
suggesting that brain vasculature may have a role in underlying mechanisms of NDs. To investigate
the drug screening capabilities of the model, the neuroactive drug methamphetamine was introduced
in the BBB influx vascular channel. Methamphetamine produced a reversible disruption of the barrier,
since removing the compound from the system stopped its effects that were leading to BBB breakdown,
like reduced expression of cell–cell junction proteins (e.g., VE-cadherin). This microfluidic model
can, therefore, be used for diverse applications, such as improving the basic knowledge on brain
pharmacokinetics, facilitating the evaluation of penetrance, efficacy and toxicity of CNS-targeted drugs,
or assessing BBB function and mechanisms in both normal and diseased states [64].
Bang et al. [65] established a 3D BBB microfluidic model, based on a vasculogenesis-like process.
The device consisted of a PDMS slab containing one middle chamber and two channels side by side
(vascular and neural channel). A vascular network self-assembled in the middle channel on a fibrin
hydrogel over a 3-day period, by co-culturing human umbilical vein endothelial cells (HUVEC) and
primary human lung fibroblasts, while in the adjacent micropost traps, astrocytes and rat cortical
neurons were grown in direct contact with the capillaries, in order to complete the BBB model.
The two channels allowed to independently supply different types of media for the neural and
endothelial cells (neurobasal medium and endothelial growth medium, respectively), delivering
the best combination of medium. Thus, an optimized co-culture environment not only increased
cell viability, but also led to further inducement of relevant BBB characteristics, including greater
expression of TJs protein (e.g., ZO-1), presence of synaptic structural features and a higher degree of
neurovascular interfacing (establishment of more direct connections between astrocytic end-feet and
endothelial cells). Correspondingly, this model had low permeability coefficients for 20 and 70 kDa
dextran, comparable to reported in vivo BBB values [65]. While the developed platform is great for
improving tissue-level function, presenting substantial potential to majorly accelerate brain disease
neuropharmacological research, it cannot be considered a complete NVU model, since more cells
would need to be included [65].
Partyka et al. [66] investigated in their 3D model the effects of mechanical stimuli exerted by
blood flow on both BBB permeability and waste transport. The device consisted of two parallel
microchannels with inlets and outlets, and a hydrogel at the centre of the microchannels. The hydrogel,
composed of hyaluronan, collagen type I and Matrigel, supported the co-culture of human cerebral
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microvascular endothelial cells (hCMEC/D3) with astrocytes, for 3-4 days. As shown in previous
studies [51,67], the findings suggest that both shear stress and cyclic strain increase TJs formation and
decrease transendothelial permeability, significantly improving the overall BBB integrity. Accordingly,
compared to static controls, vessels exposed to fluid flow, with or without stretch, had enhanced
TEER values and lower permeability coefficients for dextran 4 kDa, thus confirming that these factors
indeed contribute to the maintenance of proper BBB function. It was also demonstrated that vessel
wall pulsation provides a convective force that facilitates retrograde transport along the basement
membrane of the cerebral microvasculature, including of metabolic waste products. The authors
concluded their study by postulating that attenuated pulsatile waste transport as a consequence from
stiffening of the vessel walls, can possibly contribute for the pathogenesis of brain diseases [66].
Adriani and collaborators [68] developed a 3D hydrogel-based NVU system. The PDMS device was
composed of four distinct parallel channels, where the first provided neural cell culture medium, the two
central channels were used to co-culture astrocyte and neuron rat cells embedded in adjacent collagen
I matrices, and the remaining fourth hosted cerebral endothelial cells (either HUVEC or hCMEC/D3)
to mimic the blood vessel wall and provided endothelial cell culture medium. Immunochemistry
assays revealed that all three cell types were capable of growing, displaying type-specific markers (e.g.,
presence of doublecortin (DCX) for neurons, GFAP for astrocytes and VE-cadherin or ZO-1 for the
endothelial cells) and morphological characteristics. Permeability assays for dextran 10 and 70 kDa
were done in order to assess barrier functionality. The results showed that co-culture with astrocytes
enhanced BBB integrity, and that while both HUVEC and hCMEC/D3 monolayers demonstrated
size-selective penetrability, the hCMEC/D3 line had significantly higher barrier integrity compared
to HUVEC. Non-inclusion of a porous membrane within the system allowed a closer association
between astrocytes end-feet and the endothelial cells, leading to a low permeability. The presence of
astrocytes was also important for neuron growth, as demonstrated by the increased number of neurite
segments in co-culture conditions, compared to neurons in monoculture. To best demonstrate the
model’s BBB restrictiveness and its application for compound testing, the authors conducted a test
in which glutamate, a neurotransmitter, was injected into the endothelial cell channel and its ability
to trigger neuronal activity was assessed by calcium imaging and c-Fos expression. In contrast to a
microfluidic system without endothelial barrier, the developed model had a significant decreased
calcium concentration in the neurons and a C-Fos immunopositive staining, implying the presence of
an intact barrier that was able to restrict the passage of the test compound and thus, consequently,
restrict neuron activation. It is suggested that this platform will be useful for neurovascular studies,
such as assessing drug effects on neural function [68].
Campisi et al. [69] co-cultured human induced pluripotent stem cell-derived endothelial cells
(hiPSC-ECs) with human primary astrocytes and pericytes in a microfluidic platform. The mixture
of cells was injected with a fibrin gel to the central microchannel of a PDMS device. The hiPSC-ECs
underwent self-assembly in the 3D matrix into a microvascular network comprised of small perfusable
lumens, with pericytes and astrocytes surrounding and adhering to them, thus emulating the in vivo
BBB neurovascular organization. Immunochemistry and real time RT-PCR assays, performed after 7
days, validated the formation of a functional barrier, with gene expression of several BBB membrane
transporters (e.g., P-gp, MRP1 or GLUT-1), TJs proteins (ZO-1, occluding and claudin-5) and ECM
proteins (laminin and collagen V) in the triple co-culture being significantly increased compared
with an iPSC-ECs monoculture or an iPSC-ECs/astrocytes co-culture. This BBB model was robust
and physiologically relevant, displaying low permeability and transport selectivity dependent upon
molecular weight. Indeed, permeability values of 2.2 × 10−7 cm/s and 8.9 × 10−8 cm/s for 10 kDa and
40 kDa FTIC-dextran, respectively, were similar to the levels measured in rat brain, as well as previous
in vitro BBB microfluidic systems that also employed iPSC-ECs in co-culture with astrocytes or neurons.
Astrocytes and pericytes work together through paracrine signalling and juxtacrine interactions to
facilitate and stabilize endothelial vasculature organization and improve BBB formation/integrity,
therefore explaining the fact that the triple co-culture showed the best performance in terms of stability
Pharmaceutics 2020, 12, 542 17 of 37
and permeability. Furthermore, it was observed that the seeding of additional iPSC-ECs on the
side channels improved perfusability and decreased permeability, by means of filling eventual gaps,
increasing the number of connections in the vascular network and improving the overall coverage on
the boundaries of the gel region. The authors have stated that the developed model could be applied
for a number of applications, such as the study of angiogenesis and NVU function, investigation of BBB
transcytosis, or evaluation of biological events that occur in NDs and of metastatic cancer extravasation
to the brain [69].
More groups have also come up with recent 3D BBB microfluidic models using human iPSC [70–72].
Jamieson et al. [70] co-cultured iPSC-derived BMECs and pericytes in a cylindrical channel surrounded
by collagen I. They observed the formation of a confluent monolayer without discontinuities,
direct BMECs-pericyte contact and abluminal localization of the pericytes. The permeability
of Lucifer yellow for the co-culture was comparable to that of BMECs microvessels without
pericytes [70]. This contrasts with other BBB studies, where pericyte co-culture improved the
barrier restriction [69,73,74]. These discrepancies may be due to a series of factors, such as variability
in the culture and assay conditions, or even iPSC-line background. Linville et al. [71] cultured
iPSC-derived BMECs within collagen I-coated microchannels in a PDMS microfluidic chip, leading to
the creation of a model that resembles human brain post-capillary venules in terms of their cylindrical
geometry, cell–ECM interactions and shear flow. This 3D perfused microvessel model had similar
restrictive permeability to post-capillary venules in rats. Moreover, in comparison with self-organizing
BBB approaches employed to mimic vasculogenesis, this model has the advantage of achieving
physiological barrier functionality after only two days of culture, without the hassle of astrocyte or
pericyte co-culture [71]. Motallebnejad et al. [72] created a BBB-on-a-chip that supports flow and
where a co-culture of hiPSC-derived BMECs with astrocytes embedded in a 3D hydrogel was achieved.
Apical addition of TGF-β1 conducted to a reduction of TEER values and astrocyte activation, putting
forth the ability of the system to be used as a BBB disruption model. Furthermore, since all the cultured
cells derived from the same hiPSC line, it could also enable genetic and rare disease modelling [72].
To get further insights into the BBB system of efflux transporters, which is generally not the
main focus of in vitro brain platforms, Lee et al. [75] established a CNS angiogenesis microfluidic
model containing a co-culture of human HBMECs, astrocytes and pericytes in a fibrin/hyaluronic acid
hydrogel, seeded in the central microchannel (Figure 4b). Fibroblasts were also added to a side channel,
as a source of angiogenic factors. Confocal images showed that after 7 days, the microvasculature
resulting from the triple culture was fully mature and perfused, presenting physiologically relevant
BBB characteristics, including in vivo 3D-like morphological phenotypes, direct cellular interactions
(astrocyte and pericyte covering the vessels), increased adherens/TJs expression and limited vessel
dilation, related to the minimized vessel diameter of about 34.64 µm (the smallest engineered vessel
diameter ever reported). Additionally, compared to a monoculture of ECs, the triple co-culture had
lower permeability for both 10 and 70 kDa FITC-dextran, which further confirmed the integrity and
barrier function of the vascular network. To demonstrate the functionality of efflux transporters, the
authors conducted a calcein acetoxymethyl (calcein-AM) assay, again under mono- and triple-culture
conditions. Calcein-AM is a compound that when inside the cells is rapidly hydrolysed to fluorescent
calcein (leading, therefore, to an increase in fluorescence). The developed model had a significantly
lower initial calcein intensity, indicating a higher expression of efflux transporters that pumped out
more calcein. Furthermore, fluorescence intensity on the endothelium was tracked over a 10h period,
after treatment with P-gp inhibitors (valspodar and elacridar). As expected, for both culture conditions,
the remaining fluorescence intensity was higher, since less calcein was being effluxed. However,
compared with monoculture conditions, the triple co-culture had a more prominent difference between
treated and non-treated groups. Under inhibitor treatment, the effect of efflux transport was diminished,
leading to a higher remaining calcein intensity than in non-treated groups (8.96- and 2.10-fold higher for
valspodar and elacridar, respectively). This was the first in vitro BBB model that allowed reconstitution
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and regulation of the efflux transport system under 3D microvasculature condition, highlighting its
potential for application in CNS drug penetration studies [75].
In an interesting study, Wang et al. [76] converged two approaches–organoids and microfluidic
devices-to develop a 3D brain organoid-on-a-chip that recapitulates the early human brain development
(Figure 4c). The culture of hiPSCs-derived embryoid bodies (EBs) in a Matrigel® within the microdevice,
under mechanic perfusion flow, led to the in-situ growth and maturation of self-organized organoids.
The microfluidic organoids exhibited well-defined neural differentiation, regionalization and cortical
organization. Moreover, compared to brain organoids under static culture conditions in a Petri dish, the
on-chip organoids had superior expression of cortical layer markers (TBR1 and CTIP2) and increased
cell viability (<10% apoptosis vs. 40% apoptosis), indicating the importance of perfusion flow and 3D
ECM in enhancing brain organogenesis and creating a biomimetic microenvironment that supports
prolonged culture. The main disadvantage of this technique is that organoids are not individually
addressable for screening purposes. However, it holds promise for fundamental neurodevelopment
and disease modelling studies [76]. In a follow-up paper [77], the same authors demonstrated the
applicability of this platform, by assessing the impact of nicotine in prenatal brain development. It was
found that nicotine exposure elicited neuronal dysfunction, with the organoids presenting impaired
neurogenesis, specifically brain regionalization and cortical development [77].
For in vitro studies of neurovascular pathology, Cho et al. [78] designed a 3D BBB model consisting
of an assembly of horizontal parallel microchannels beside a tube-shaped macrochannel in a single
layered microfluidic chip (Figure 4d). The macrochannel was coated inside with a poly D-lisine (PDL)
and a collagen I gel, promoting the adhesion of the RBE4 cell line and leading to the formation after
2–3 days of an endothelial cylindric monolayer that resembles the geometry of small blood brain vessels.
The formation of a tight BBB was confirmed by confocal imaging of the positive immunostaining of TJs
proteins (ZO-1 and VE-cadherin). Permeability assays with 40 kDa dextran were done in order to test
the barrier function. The dye was introduced into the lumen of the macrochannel and the increase in
fluorescence on the side channels was monitored. The presence of the BBB slowed the outward flux of
the dye, since it took longer to reach gradient saturation in the developed model (7 min), compared to a
device without barrier (less than 4 min). Moreover, it was also able to block and inhibit more efficiently
neutrophil transmigration upon addition of interleukin 8 (IL-8), a chemoattractant. For probing
neuroinflammation response, the BBB was exposed to TNF-α. Elevation of several cytokines (e.g.,
VEGF, CX3CL1, CINC1, TIMP1, etc.) led to the conclusion that an inflammatory effect was elicited
on the BBB model. The platform was also used to study ischemia, induced by oxygen and glucose
deprivation followed by reoxygenation. An increase in ROS and Rho-associated protein kinase (ROCK)
levels was observed, as well as a decrease by more than half in ZO-1 expression. Antioxidant treatment
with edavarone and Y-27632 (a ROCK inhibitor) had limited protective effects in restoring BBB integrity:
ZO-1 levels increased slightly after 3h but decreased again after 6h. This can be due to the fact that
ischemia is not only a result of oxidative stress, but also hypoxia and other inflammatory factors [78].
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5. Neurodegenerative Diseases Microfluidic Models
As previously discussed in prior sections, microfluidic devices are able to emulate brain
microvasculature-related events, for instance, angiogenesis, inflammation or BBB changes [79]. It is
known that BBB dysfunction underlies the development of NDs. By reconstituting such dynamic
conditions of the human brain, a validated BBB-on-a-chip can be used to address the critical need to
improve the understanding of the pathological mechanisms of NDs [32,79]. Furthermore, since CNS
models that mimic NDs typically require controllable fluid delivery and long-term culture duration,
microfluidics come forth as an advantageous and reliable platform to study these disorders [39].
A summary of the main findings of the studies that will be discussed in this section can be found in
Supplementary information (Table S1).
5.1. Alzheimer’s Disease
AD is a neurodegenerative disease that is the most common cause of dementia globally.
Pathological hallmarks of AD include the presence of extracellular aggregates of amyloid β
(Aβ) plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau protein [80,81].
Anomalous cleavage of the amyloid precursor protein (APP) by β-secretases and γ-secretases leads
to the production of insoluble Aβ fibrils, which suffer oligomerization and aggregation into senile
plaques. In turn, Aβ concentration triggers the hyperphosphorylation of the tau protein, followed by
its polymerization into neurofibrillary tangles. There appears to be a synergistic neurodegenerative
effect of these cytotoxic proteins, with the recruitment of microglia cells and formation of a local
inflammatory response also potentiating neuronal damage and death [24,81].
AD is associated with three general stages-mild (early), moderate and severe-, with progressive
memory deficits and cognitive decline [82]. Neuropsychiatric symptoms may manifest over the course
of the disease, including irritability, diminished insight or restlessness. In nearly 30 to 50% of the
cases, psychotic symptoms such as hallucinations or delusions of persecution are also present [82].
The plaques and neurofibrillary tangles are mainly detected in cortical and limbic areas of the brain.
There is moderate cortical atrophy, accompanied with enlargement of the frontal and temporal horns
of the lateral ventricles, and a decrease in brain weight [80,81]. Given that AD is a long-term process,
with a lengthy preclinical asymptomatic phase characterized by pathological changes that begin 20 to
30 years prior to the appearance of the first clinical signs, it should not be excluded that cognitively
normal individuals might also have the disease [80,82].
Clinical diagnosis entails a thorough assessment of previous medical records and family history
to rule out other conditions that may cause similar symptoms, physical and neurological examination,
neuroimaging (PET scan, MRI, etc.), and neuropsychological testing, often in combination with
detection of biomarkers like Aβ and τ protein in cerebrospinal fluid (CSF) samples from patients [81,82].
To date, accurate identification of AD is still hard, and both clinical diagnosis and post-mortem
histopathological examination of the brain are needed in order to give a conclusive diagnosis. This is
especially true in the early stages of the illness, primarily because the symptoms are dismissed as a
normal result of the aging process. The strongest known risk factor for the development of AD is, in
fact, aging, affecting 10% of people over the age of 65 and about 50% of people older than 85. Family
history of AD, existence of one or more apolipoprotein E (ApoE) gene alleles, cardiovascular risk
factors, and moderate or severe brain traumas can also account for the aetiology of the disease [82].
AD research has been majorly committed to the development of therapies that can reduce
aggregates of toxic forms of Aβ and tau protein, with several of them having reached Phase III
clinical trials (e.g., NGP 555, verubecestat, immunotherapy vaccines such as aducanumab, etc.) [81,83].
The latest progress is the study by Davtyan et al. [84], wherein they tested in bigenic T5x mice a
combinatory therapy that concurrently targeted both Aβ and tau protein, successfully removing
plaques and neurofibrillary tangles. Furthermore, the vaccine might also be used as a preventive
strategy, since it can likewise decrease the concentration of those proteins in serum and brain extracts,
thus averting their deposition [84]. In fact, avoiding plaque accumulation seems to be a better goal, since
Pharmaceutics 2020, 12, 542 21 of 37
the removal of plaque deposits might merely result in holes in the neuronal synapses, a damage that can
be difficult to overcome. In this field, Novartis has put forth the CAD106 vaccine, presently in Phase
II/III study, designed to stimulate the production of Aβ-antibodies [83]. Nonetheless, therapy failure
is often frequent, due to unfavourable pharmacokinetics and pharmacodynamics of the drugs [81].
Presently, cholinesterase inhibitors (e.g., donepezil) and memantine, a non-competitive blocker of the
NMDA receptor, are available for the treatment [85].
Park et al. [86] were able to show the neuroinflammatory role of microglia in AD pathogenesis,
and their influence in neuron death. The investigators developed a 3D human AD triculture system,
by culturing neurons and astrocytes expressing mutant APP in a central chamber coated with Matrigel,
with human immortalized SV40 microglia being added in surrounding angular chambers at a later time.
The neurons and astrocytes expressed late-stage AD hallmarks, including Aβ aggregation, abundant
tau protein formation and secretion of pro-inflammatory cytokines and chemokines, thus recapitulating
many of the features of this disease in a single microfluidic platform. Compared with controls, in this
model, infiltrating microglia migrated quicker and induced greater neuron toxicity/death by a pathway
involving TLR 4 and interferon-γ (IFN-γ). This was demonstrated by the fact that using IFN-γ and
TLR4 neutralizing antibodies led to a reduction in microglial activation and, consequently, neuronal
toxicity [86].
Concave microwell arrays in a microfluidic system were used to seed and culture for up to
10 days neural progenitor rat cortical cells, with or without fluid flow, evaluating thereafter the
neurotoxic effects of Aβ on the formed 3D gel-free neurospheroids [87]. The group demonstrated
that, compared to static cultures, the neurospheroids grown under perfusion conditions similar to
those of the CSF in the brain, had generally larger sizes and greater neurite extension, resulting
in a more complex and robust neural network. Furthermore, cell staining for β-III tubulin marker,
denoted an enhanced differentiation of the progenitor cells into mature neurons. These differences
could be the result of a better access to oxygen and nutrients, and continuous clearance of metabolic
wastes provided by the fluid flow. Afterwards, the neurospheroids were exposed to Aβ, in the same
experimental settings. The results showed that Aβ was significantly more toxic to neurospheroids
under flow conditions induced by an osmotic pump, causing greater destruction of neural networks
and significantly decreasing cellular viability [87].
Cho et al. [88] elucidated the role of Aβ on microglial accumulation. They cultured human
microglial cells in a microfluidic platform and studied their response to chemotaxis of week-long
gradients of soluble Aβ and surface-bound (insoluble) Aβ (Figure 5a). Time-lapse microscopy showed
that soluble Aβ drives microglia migration towards the central chamber, explained by Aβ-induced
secretion of the chemoattractant MCP-1. Furthermore, microglial motility was decreased in areas with
Aβ fibril-coated surfaces, which correlates to what is seen in vivo in AD brains, where microglia cells
form a stable association with Aβ deposits. All in all, there seems to be a synergistic effect between
soluble and insoluble Aβ on microglial recruitment and localization during the neurodegenerative
process of AD [88].
Song et al. [89], to the best of our knowledge, were the first group to deliver direct experimental
evidence of extracellular Aβ spreading through neuronal connections. They demonstrated retrograde
transport of Aβ from axons to the neuronal cell bodies, being subsequently secreted and transmitted to
neighbouring neurons [89]. Deleglise et al. [90], examined the impact of Aβ on neuron degeneration
patterns. By using a microfluidic chip comprised of two chambers separated by microchannels,
the scientists were able to culture primary cortical and hippocampal mouse neuronal cells and
isolate soma-dendrites from axonal projections, applying afterwards Aβ peptides to the different
cellular compartments. It was found that local somatodendritic Aβ deposits trigger a rapid distal
presynaptic loss and disconnection, long before soma/dendrite abnormalities and death start to occur
(a phenomenon referred to as “dying-back process”). On the contrary, when the axons where treated
with Aβ, the same was not observed. This demonstrates local Aβ deposits are efficient in generating
signalling pathways (e.g., caspase and NAD+ pathways) that lead to early degeneration in anatomically
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distant areas of the neuron [90]. To this day, there are doubts about which molecular entity of Aβ is the
most toxic and responsible for causing AD. Choi et al. [91] have looked into this matter. They exposed
neurons (differentiated from rat neuronal progenitor cells) adhered onto a microchannel of a PDMS
microchip to a slow gradient of Aβ oligomeric assemblies for 3 days. Although fibrilization increased
considerably over time, cell viability did not statistically change. This suggests that Aβ fibrils do not
have a significant role in neurotoxicity, but rather oligomeric assemblies potentially contribute to the
neurodegeneration in AD [91].
To determine the nature of the tau responsible for neuron-to-neuron transmission, Takeda et al. [92]
developed a compartmentalized 2D microfluidic platform comprised of three interconnected chambers
wherein two sets of neurons where cultured. The authors collected different tau species from cortical
extracts and interstitial fluid of human and transgenic mice brains, and their propagation through
the synaptic connections was observed over the course of 14 days. A soluble high molecular weight
phosphorylated tau was identified as the bioactive form, undergoing direct trans-synaptic transport and
initiating the seeding that leads to the formation of aggregates within the cytoplasm of the neurons [92].
Wu et al. [93] further demonstrated in a study using a tripartite microfluidic device that cell to cell
propagation is capable of inducing tau aggregation in downstream neurons [93].
5.2. Parkinson’s Disease
First described in 1817 by James Parkinson, PD is after AD the second most prevalent
neurodegenerative disease [94]. Estimations point towards 1-3% of the population over the age
of 65 developing this illness, with people under 40 years rarely being affected [95]. PD involves
progressive disruption and loss of dopaminergic neurons in the substantia nigra pars compacta, with
substantial depletion of dopamine [94]. Neuronal loss is also extensive in cholinergic (basal nucleus
of Meynert), serotonergic (raphe nuclei) and noradrenergic (locus coeruleus nuclei) systems, in the
brainstem (dorsal motor nucleus of the vagus nerve and pedunculopontine nucleus), in the cerebral
cortex, optic bulb and autonomic nervous systems [95,96]. Accumulation of cytoplasmic inclusions
consisting of α-synuclein (αSyn) aggregates, called Lewy bodies, is likewise present in the affected
areas. It is not known how Lewy bodies specifically relate to the progression of the disorder, but
nevertheless, the formation of these aggregates induces neurodegeneration [94,95]. Since the disease is
heterogeneous and multifactorial, protein aggregations are not the only underlying reason for neuronal
loss. Multiple other cellular processes, such as mitochondrial dysfunctions, neuroinflammation,
oxidative stress, impaired bioenergetics, altered activity of calcium channels or genetic mutations,
equally contribute to PD development of PD [95].
PD manifests itself through motor and nonmotor symptoms. Dysfunctions of the somatomotor
system comprise resting tremor (usually unilateral, in the beginning), bradykinesia (slowness of
voluntary movements), impaired gait, postural instability and rigidity. The diagnosis is usually
made after the onset of one or more of these core motor features [95,96]. Throughout the course
of the disease, nonmotor symptoms also arise: cognitive decline, mood and sleep disorders, and
dysfunction of the autonomic nervous system, including constipation, orthostatic hypotension, changes
in thermoregulation, incontinence or erectile impotence. These can be as debilitating as the motor
symptoms, increasing disability and reducing quality of life. Some of the key signs are a direct
result of neurodegeneration, while other clinical features are suspected to be caused by aberrant
activity patterns within surviving neurons [94,96]. PD is still incurable, but management of the
disease through replacement therapy with dopamine precursor levodopa or dopamine agonists,
can be helpful in symptomatic relief [95,96]. Additional options include dopamine agonists,
catechol-O-methyltransferase (COMT) inhibitors, anticholinergics and monoamine oxidase-B (MAO-B)
inhibitors [97].
Moreno et al. [98] were successful in differentiating human neuroepithelial stem cells
embedded in Matrigel into dopaminergic neurons, using a 3D microfluidic phase-guided bioreactor.
Immunofluorescence staining showed a differentiation efficiency of around 19%, which was comparable
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to that of a macroscopic culture. The biocompatibility and biological fidelity of this new model were
further confirmed by the electrophysiological activity of the dopaminergic neurons. This model
could be an economically efficient route to personalized drug discovery for PD [98]. Kane et al. [99]
established the first fully automated 3D brain-on-a-chip (termed “Pelican”) for microfluidic cell culture
and real-time monitorization through image acquisition. Using the Pelican, they differentiated PD
patient stem cells into midbrain dopaminergic neurons. Long-term maintenance was achieved (over
100 days) and on day 24, quality control of the culture was assessed. Immunostaining revealed
the presence of fully mature neurons within the microchips and calcium imaging confirmed their
electrophysiological activity. The authors denote that this is a flexible cost-effective approach to not
only model PD, but also for other diseases, enabling adaptation to various experimental protocols.
Integration of new modules could expand even more the array of possible in vitro tests [99]. In a second
study, Bolognin et al. [100] also resorted to patient stem cells to generate a 3D microfluidic model with
neurons carrying the LRRK2-G2019S mutation (responsible for autosomal-dominant PD). The mutation
led to progressive dopaminergic degeneration with mitochondrial defects. When compared to a 2D
system, the 3D culture presented more robust PD endophenotypes, thereby demonstrating a higher
degree of differentiation into the intended specific subtype. Treatment with LRRK2 inhibitor 2 was
effective in lessening neurodegeneration and in rescuing some dopaminergic phenotypes, indicating
that this platform may be useful for drug screening purposes [100].
Fernandes et al. [101] explored the molecular mechanisms involved in PD using a microfluidic chip.
The device consisted of two culture chambers interconnected by three channels. Integrated pneumatic
valves allowed fluid flow control and communication between the two chambers. In the first experiment,
the transmission of αSyn between two cell populations (naïve human H4 neuroglioma cells and H4
cells expressing αSyn tagged with GFP fluorescent marker) was assessed. They permeabilized the
membrane of the disease-model cells to release αSyn to the medium, monitoring thereafter the protein
diffusion to the other chamber of the device, where the healthy naïve H4 cells were present. There was
no detectable uptake of αSyn-GFP on the part of naïve H4 cells. Several possible explanations might
justify this result, such as: too low concentration of αSyn-GFP being released, rapid degradation of the
molecule or even the high molecular weight of GFP affecting the spreading of αSyn. Nevertheless,
the authors point out that the platform is still valid to study cell–cell communication via soluble
factors. The second experiment entailed evaluating the impact of activated N9 microglia cells on the
neuron-like H4 population. H4 cells co-cultured with the LPS-activated N9 cells presented almost
2-fold higher ROS levels than the controls, confirming the interplay and crosstalk between the two cell
lines [101].
Freundt et al. [102] seeded and cultured primary neurons for one week in a microfluidic device, in
the presence of αSyn fibrils. Using live cell imaging and immunofluorescence, the group showed that
the fibrils are internalized and transported anterogradely along the axons until reaching the neural
soma, following which, they are released and transferred to other neurons. This mechanism can help
explain the characteristic pattern of neuron-to-neuron spread of Lewy bodies between connected brain
areas, such as the neocortex and the limbic system [102].
Mitochondrial trafficking defects are implied in PD pathogenesis. Bearing this in mind,
Lu et al. [103] created a compartmentalized microdevice that allowed visualization of mitochondria
transport in dopaminergic axons. Upon application of the PD-mimetic toxin MPP+, a rapid (<1 h) and
selective decrease of mitochondrial movement was observed [103].
5.3. Multiple Sclerosis
MS is an autoimmune inflammatory neurodegenerative disorder, characterized by nerve
demyelination and axon damage. Myelin proteins start to get recognized as foreign components by the
immune system, resulting in the destruction of the myelin sheath [97]. Apoptosis of oligodendrocytes,
the cells responsible for forming and maintaining myelin, instigates further neuronal breakdown and
loss of function. Over a dozen of drugs with different mechanisms of action have been approved by
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the Food and Drug Administration (FDA) to treat MS attacks (e.g., dimethyl fumarate, interferon-β
(IFN-β), fingolimid, teriflunomide, ocrelizumab, etc.) [97].
Given the importance of the possibility of remyelination in MS, Kerman et al. [104] combined
stem cell biology and microfluidic technology to differentiate mouse embryonic stem cells into
myelinating oligodendrocytes, subsequently assessing and quantifying myelin formation over several
days. Live imaging and confocal analysis led to the observation that oligodendrocytes anchor to the
bare axons before wrapping them and forming the myelin sheets. This model is a suitable tool to better
comprehend the myelination process and to unravel novel treatments for demyelinating diseases like
MS [104].
Hosmane et al. [105] created a co-culture microfluidic system to study axons-microglia interactions
(Figure 5b). The group induced axon degeneration and found that there is microglial clearance and
phagocytosis of unmyelinated axonal debris through toll/interleukin-1 receptor domain-containing
adapter inducing interferon-β (TRIF)—a Toll-like receptor adapter protein—, and through p38
mitogen-activated protein kinase (MAPK), thus seemingly showing the importance of these cells in
contributing to neural repair after peripheral insult [105].
5.4. Amyotrophic Lateral Sclerosis
In ALS, a motor neuronal disease, there is progressive degeneration of upper and lower motor
neurons in the corticospinal tract. In consequence of the deterioration, communication between the
motor neuron and the muscle is lost. ALS usually begins in the 40s or 50s with painless, localized
weakness of the arms and legs, gradually evolving to affect most muscles, with patients dying within 3
to 5 years of the initial diagnosis. Although the exact mechanism is still unclear, it is thought that several
processes contribute to the development of ALS, including genetic factors, glutamate excitotoxicity,
inflammation, mitochondrial and enzymatic dysfunction or ROS [32,97]. Two forms of the illness are
known: sporadic ALS, the most prevalent, comprising around 90% of the cases, and familial ALS,
where there is a family history of the disease relating to a genetic component. Until now, no effective
treatment was found to cure ALS. Only two drugs approved by FDA, riluzole and edavarone, provide
a very limited enhancement in survival [32,97].
Recently, several microfluidic models have allowed to better understand neuromuscular junction
(NMJ) connectivity and pathophysiology. For instance, Machado et al. [106] developed a system
that is designed in such a way that motor neurons in an outer compartment are able to extend
their axons through an array of microchannels and form NMJ with myofibres seeded in the central
compartment. The validation of key NMJ features, such as axon outgrowth and proper myofibre
contraction, were verified by immunostaining with β3-tubulin antibody and optogenetic stimulation,
respectively. By co-culturing the motor neurons derived from mouse embryonic stem cells with
astrocytes expressing superoxide dismutase enzyme 1 (SOD1) (an ALS-linked mutation), and with
myofibers, the authors observed denervation and diminished contractile response, central features of
this disorder. Furthermore, they verified that through applying the RIPK1 inhibitor Necrostatin, an ALS
drug candidate, the phenotype could be reversed, thus improving motor neuron survival and reducing
the deterioration of motor innervation [106]. Southam et al. [107] demonstrated the importance of glia
cells in motor neuron growth and spreading in a physiologically relevant NMJ microfluidic model [107].
In a 2013 study, Ionescu et al. [108] also established a microdevice that enabled the efficient monitoring
of neuron-muscle formation, maintenance and communication through imaging, calcium transient
recording and muscle contraction assay [108].
Evidence suggests that non-cell autonomous processes have a role in ALS neurodegeneration,
with neighbouring glial cells such as astrocytes secreting proinflammatory cytokines and inducing
further neuronal death [97]. To better understand these indirect interactions and extracellular metabolic
communication, Kunze et al. [109] co-cultured neurons with astrocytes that overexpress either a
wild-type (WT) or mutated SOD1, assessing afterwards the response in terms of neuronal cell activity.
They showed that the cortical neurons in metabolic contact with SOD-mutant astrocytes had a reduction
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in cell density of about 45%, as well as loss in synapsin protein expression. In contrast, SOD-WT
overexpressing astrocytes reduced oxidative stress on cortical neurons that were in close metabolic
contact [109].
Spinal motor neurons are considered to be highly vulnerable in ALS. Sances et al. [110] showed that
co-culturing brain microvascular endothelial cells with motor neurons, both derived from iPSC, resulted
in vascular-neural interaction and activation of specific spinal cord developmental genes, considerably
enhancing in-vivo like spinal neural tissue maturation, function and signalling. This model could
help unravel the mechanisms behind motor neuron-related diseases, provide a platform to infer the
penetrance of prospective ALS therapeutics into the blood-spinal cord barrier and study the modulation
of neural activity [110].
Osaki et al. [111] created a human ALS microfluidic model, by co-culturing motor neurons
spheroids derived from iPSC of a patient with sporadic ALS with 3D skeletal muscle fibres surrounded
by an endothelial cell layer, in a collagen gel. Compared to a normal motor neuron model (control), the
ALS system had motor neuron degeneration, increased muscle apoptosis and atrophy, and reduced
contraction force. To study potential drugs that might confer neuroprotection, both the control model
and the ALS model were treated with rapamycin (an mTOR inhibitor) and bosotunib. With the
tested therapeutic agents, the disease model exhibited less neurotoxicity, superior motor neuron
survival and improved muscle contraction. This was attributed to an induction and up-regulation of
autophagic processes, and to the degradation of TAR DNA binding protein 43 in the motor neurons.
Although the endothelial cell barrier is known to hinder drug penetration, rapamycin and bosotunib
co-treatment reduced the expression of P-gp efflux pump, significantly increasing muscle contraction
force. Furthermore, to mimic glutamate excitotoxicity, the control culture was exposed to an excess of
glutamic acid for 14 days. The results showed that it caused motor neuron dysfunction and death,
along with neurite regression and muscle atrophy. Given that other NDs such as AD or PD have also
been associated with muscle strength, the authors suggest that the developed microplatform could be
a robust model to facilitate the investigation of neurovascular coupling in those cases as well [111].
Tan et al. [112] studied the neurotoxicity of β-methylamino-L-alanine (BMAA), a cyanotoxin that
has been linked with neurodegeneration in ALS. Using a microfluidic device, the group treated mature
rodent cortical neurons with BMAA, observing axonal degeneration at sublethal concentrations, as well
as rapid BMAA transcellular forward spreading to other neurons, which could possibly be associated
with ALS progression [112].
5.5. Huntington’s Disease
HD is an illness with autosomal dominant inheritance caused by an expansion of CAG trinucleotide
repeats in the gene encoding the protein huntingtin, resulting in the generation of a mutant huntingtin
(mHTT). mHTT induces dysregulated gene expression, formation of aberrant toxic inclusion bodies,
impaired protein folding and degradation, mitochondrial dysfunction, among other things, all of which
lead to neuronal degeneration and death [32,97]. The earliest symptoms are rapid and involuntary
movements that affect mostly facial muscles and distal limbs, termed “chorea”. Currently, no approved
therapy can delay the advance of HD. However, tetrabenazine is frequently used to supress the
chorea [97].
Virlogeaux et al. [113] reconstituted a corticostriatal network in a microdevice, demonstrating that
presynaptic defects contribute more to the progression of HD than previously thought. Indeed, HD
cortical neurons expressing mHTT caused functional and signalling impairments in striatal neurons
(e.g., compromised glutamate release), altering the global integrity of the whole network. On the other
hand, WT cortical neurons were sufficient to rescue and restore the circuit in HD striatum, improving
survival signalling. It can be concluded therefore that the genetic status of presynaptic neurons plays a
crucial role in HD striatum dysfunction and neurodegeneration. Some of the benefits of this system
remarked by the authors are its suitability for spatial and high temporal resolution imaging, testing
drugs for the treatment of HD or getting further insights into pathophysiological mechanisms [113].
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Vatine et al. [114] used patient diseased iPSC lines to create an HD-on-a-chip and investigate the
BBB dysfunction in this disease (Figure 5c). Permeability for dextran of several molecular sizes was
increased, suggesting a significant disruption of the integrity of the vascular barrier. The model may
thus be used for several aspects of disease modelling, including predict interindividual variability in
BBB function and in CNS drug penetrability [114].
Pharmaceutics 2020, 12, x FOR PEER REVIEW 27 of 38 
 
 
 
Figure 5. Schematic representation of some microfluidic models for neurodegenerative diseases, 
namely: (a) Alzheimer’s disease, (b) Multiple sclerosis, (c) Huntington’s disease. Reprinted and 
adapted with permission from: (a) Cho et al. [88], (b) Hosmane et al. [105], (c) Virlogeux et al. [113]. 
6. Microfluidic Synthesis of CNS-Targeted Nano/Microcarriers and Other Compounds 
Microfluidics production of NPs is a relatively established research field. However, when it 
comes specifically to the microfluidic synthesis of nano-/microcarriers or other compounds (e.g., 
Figure 5. Schematic representation of some microfluidic models for neurodegenerative diseases,
namely: (a) Alzheimer’s disease, (b) Multiple sclerosis, (c) Huntington’s disease. Reprinted and
adapted with permission from: (a) Cho et al. [88], (b) Hosmane et al. [105], (c) Virlogeux et al. [113].
Pharmaceutics 2020, 12, 542 27 of 37
6. Microfluidic Synthesis of CNS-Targeted Nano/Microcarriers and Other Compounds
Microfluidics production of NPs is a relatively established research field. However, when it comes
specifically to the microfluidic synthesis of nano-/microcarriers or other compounds (e.g., radiotracers)
meant to target the CNS, either with therapeutic or diagnostic purposes, to the best of our knowledge,
only a few studies have been published, which we will proceed to describe in this section.
The human immunodeficiency virus (HIV) is able to infect the brain and use it as a reservoir
for replication. Bearing this in mind, Martins et al. [19] prepared transferrin functionalized
poly(lactic-co-glycolic) acid (PLGA) NPs, loaded with efavirenz (an anti-HIV drug), in order to
target the BBB and treat HIV neuropathology (Figure 6a). Relative to a conventional nanoprecipitation
technique, the microfluidic approach produced particles with a smaller size (83 nm versus 133 nm),
higher drug loading (10.8% versus 3.2%) and association efficiency (80.7% versus 32.7%). A sustained
in vitro release was observed, with the nanosystems releasing 50% of the drug within 24h. Although the
functionalized NPs had a 1.3-fold higher permeability than the free drug across a hCMEC/D3 in vitro
model, showing their capability to interact more efficiently with BBB cells and leading to a greater
anti-HIV effect, in regard to plain PLGA NPs, the transferrin formulation did not potentiate efavirenz
membrane permeation. Furthermore, the NPs were found to be non-haemolytic and non-toxic to BBB
endothelial and neuron cells (metabolic activity above 70%), being therefore safe for the intended
intravenous administration and opening new doors for advancements in HIV neuropathology [19].
Precise imaging of cerebrovascular structures can significantly contribute to the timely diagnostic
and treatment of NDs, including brain tumours. Several modalities are available, such as near-infrared
II (NIR-II) fluorescence or photoacoustic imaging. For this purpose, Guo et al. [115] synthesized
a theranostic nanosystem, by producing conjugated polymer NPs with a uniform size of 50 nm,
high imaging contrast and excellent photostability. The NPs were successfully used as contrasting
agents in dual NIR-II fluorescence and photoacoustic imaging, to efficiently and noninvasively map
deep microscopic brain tumours in nude mice after focused ultrasound (FUS) induced BBB opening.
The results from cytotoxicity assays in bEnd.3 and C6 cells (> 95% cell viability) and the fact that
no inflammatory lesions or tissue damage were found in organs collected from the treated mice,
demonstrated that the nanocarriers are highly biocompatible [115]. In another study performed by
this group in 2019 [116], it was possible to obtain high-resolution 3D images of the cerebral cortex
vasculature, ear blood vessels and angiogenic tumour vessels of mice, using the same techniques and
nanosystem. By optimizing the microfluidic conditions (320 of Reynolds number for fluid flow and
40% ethanol volume fraction), they obtained NPs with the smallest average diameter of 40 nm [116].
The authors envision that their polymer NPs can improve diagnostic accuracy of brain tumours and
other neurodegenerative processes, as well as enhance real-time imaging guided neurosurgical and
photothermal treatment [115,116].
Jgamadze et al. [117] developed poly(N-isopropylacrylamide) (pNIPAM) hydrogel particles
to facilitate neuronal cell growth and transplantation into the hippocampus of young adult rats.
Modification with polylysine coating led to the immobilization and adhesion of progenitor neuronal
cells on the external surface of the microcarriers, making expansion and differentiation into neurons
successful. Upon injection of the composites into the target site, robust cell implantation was observed.
Compared to conventional borosilicate glass beads, the pNIPAM microcarriers provided an increase
of 2.7-fold in the number of implanted cells. This was attributed to the rapid thermoswitching,
stimuli-responsive nature of the pNIPAM polymer, which promoted the release of the mature neurons
without damaging the neuronal processes, thus contributing to their successful long-term survival
and integration for at least 24 weeks in the rats. Furthermore, contrary to what is sometimes observed
with glass beads, no cumpling of pNIPAM particles was noted at the injection site, which indicates
low risk of long-term inflammatory responses. It can be concluded that the properties of pNIPAM
microcarriers make them a promising and efficient alternative to direct cell transplantation [117].
MicroRNA interference (miRNA) therapy holds great potential to treat many disorders, including
NDs. Samaridou et al. [118] engineered RNA-loaded cationic nanocomplexes for direct nose-to-brain
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delivery. The formation of the nanocomplexes was based on electrostatic interactions between a
modified octaarginine (C12-r8) and the RNA molecules. Two different polymers, hyaluronic acid
(HA) and polyethyleneglycol-polyglutamic acid (PEG-PGA), were used to envelop the nanocomplexes,
in order to protect against enzymatic degradation and enhance diffusion across the nasal mucosa.
Tweaking the microfluidic conditions (i.e., increasing the concentration or the flow rate ratio of
C12-r8:RNA), enabled the rapid manufacturing of a scalable nanosystem with a reproducible mean size
of 70 nm and an association efficiency close to 100%. The size of 70 nm is important, since it is known
that NPs with or less than 100 nm can enable a better transport across the BBB. The nanocarriers were
able to preserve their colloidal stability in biorelevant conditions, preventing the premature release of
the RNA. Moreover, in vitro assays revealed that the HA and PEG-PGA nanocomplexes were very
efficient in interacting and being internalized by CHO cells, given that a markedly higher cellular
uptake was observed when compared with a free miRNA mimic. Following intranasal administration
in an AD mouse model, the NPs successfully increased the therapeutic miRNA in the hippocampus
area. This, in turn, led to a decrease in the expression levels of GATA2 and Rb1 proteins, which play a
role in cell cycle and are upregulated in AD. Overall, the findings suggest that the RNA nanocarriers
developed by Samaridou et al. are a promising therapeutic strategy for AD [118].
Rungta et al. [119] reported siRNA-loaded lipid NPs effective in silencing neuronal gene
expression, both in vitro and in vivo, after intracranial injection. The NPs (lipid composition
of 3-(dimethylamino)propyl(12Z,15Z)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yl]henicosa-12,15-dienoate
(DMAP-BLP), distearoylphosphatidylcholine (DSPC), cholesterol and PEG-DMG) were produced
using a staggered herringbone microfluidic mixer (Figure 6b). The authors demonstrated that the
nanocarriers accumulate inside neurons in culture in an ApoE-dependent manner, resulting in a
100% efficacy uptake. Delivery of siRNA lipid NPs to the brain of rats was successful, leading to
widespread knockdown of neuronal genes that encode for the PTEN and GRIN1 proteins, with a
significant reduction of 72% and 51% in expression levels, respectively, compared to noninjected
controls. Furthermore, no significant immunogenicity or toxicity was detected, which is indicative of
their biocompatibility and improved safety. The results show therefore that the siRNA lipid formulation
was capable of manipulating the expression of molecular targets involved in neuronal processes,
potentially facilitating the development of gene therapies for NDs [119].
Yu et al. [120] employed lipopolymeric NPs (LPNPs) to minimize side effects and enhance
therapeutic outcomes in glioblastoma. The LPNPs encapsulated different siRNA to target four
transcription factors (OLIG2, POU3F2, SOX2 and SALL2) that lead to the formation of brain
tumour-initiating cells, which in turn drive recurrence, malignant growth and therapy resistance.
Different ratios of C15 epoxide-terminated lipids, DSPE-epoxy-PEG 2000 and polyethyleneimine 600
were used to obtain LPNPs with a size span from 40 to 135 nm. Infusion of a high dose of LPNPs
(1.5 mg/kg), achieved by intratumoral injection and convection enhanced delivery, resulted in an
extension of median survival of 19 days in patient-derived xenograft glioblastoma mouse models (50%
increased survival). In contrast, while limiting the dose attenuated tumorigenesis, it did not offer any
survival benefit. This study suggests that multiplexed nanosystems can be a viable option to overcome
the challenges posed by tumour heterogeneity [120].
Radiotracers are chemical compounds used for positron emission tomography (PET),
a non-invasive medical imaging method that can be employed for several purposes, such as to
diagnose and determine disease stage, evaluate treatment efficacy or research the biological processes
involved in pathology development, including NDs. Recently, Zhang et al. [121] reported a simple
PDMS microfluidic system for the radiosynthesis of [18F]fallypride. The highly integrated configuration
of the platform allowed to perform in a short time (~60 min.) most of the necessary reaction processes,
including [18F]fallypride concentration and purification, with good radiochemical yield (~87%) and
purity (~99%) of the tracer. It was possible to obtain a sufficient quantity of [18F]fallypride for multiple
rat injections for preclinical brain imaging studies, including of the cerebellum, left striatum and right
striatum. Despite such promising results, improvements are still needed in regards to scale-up, in order
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for microfluidics to be widely adopted as a viable alternative to traditional radiotracer production
methods [121].
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7. Challenges, Future Perspectives and Conclusions
Microfluidics has been around for 30 years, having undergone significant advances since its
inception in the early 1990s. However, it has yet to achieve its full potential within the fields of chemical
and biological experimentation [9,46]. There are several practical problems that need to be overcome if
these systems are to be used at a wider, commercial scale in the applications that have been discussed
in the prior sections [46].
When it comes to organs-on-a-chip, functionality is currently limited. Perfusion, cell injection and
sampling have a low throughput character, despite the existence of automation hardware. The initial
preparation of the device and injection of cells are often still a very manual process. Likewise, assurance
of sterile handling is critical for proper cell culture and long-term maintenance. Such procedures can be
tricky and cumbersome, if not done by a trained operator [122]. Many times, the real usefulness of these
models, as is the case of BBB/brain-on-a-chip, is translated in the fact that they allow for simultaneous
monitoring and recording of biological responses to a number of stimuli [123]. However, on-chip
sample collecting is not very practical nor feasible, since it can interfere with its operation, risking
changes in the concentration of biomarkers/metabolites and potentially generating data that cannot be
correlated with what happens in vivo [124]. The integration of more sensible and cost-effective sensors
that perform the analysis independently in the micro-space of the chip is therefore required [122,123].
Appropriate endpoints for readouts also need to be established [122]. Progresses in each of these
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areas will allow the creation of more high-end, sophisticated, but still, nonetheless, practical platforms,
that can facilitate the early diagnosis of various NDs and the development of effective therapeutic
agents [6].
Another relevant point is the source of the biological tissue [124]. Induced pluripotent stem cells
(iPSC) are a very attractive choice for cell culture in microfluidic systems, given their virtually unlimited
ability to self-renewal and differentiate into multiple somatic lineages [7,41]. Indeed, extensive work
has already been conducted in regard to the incorporation of stem cells in BBB/brain-on-a-chip for
engineering neural networks and brain tissues [41]. iPSC circumvent the ethical controversies associated
with traditional embryonic stem cells and maintain several BBB physiological attributes, including
the presence of TJ proteins and similar molecular permeability coefficients [7,124]. Furthermore,
they can be obtained from individual patients, which will drive forth not only the development of
patient-specific brain disease models, but also of personalized drug screening. Accordingly, and
despite several limitations on differentiation and maturation protocols that still subsist, iPSC is likely
to become the main cell source for organs-on-a-chip [7,124].
Regarding the production of NPs, microfluidics could offer an avenue to meet industrial scale-up
benchmarks, by means of parallelization, automation, employment of continuous flow and faster
mixing rates. This would result in an increase of the total output, reduce batch variability, and
diminish human error, potentially allowing the marketing of less expensive nanomedicines to a
greater patient population [18]. Notwithstanding the abundance of proof-of-concept publications,
there are currently no commercial nanopharmaceutics manufactured using microfluidics. Several
reasons might explain the lack of successful translation [18]. Firstly, the cost associated with mass
production and experimental implementation of microfluidic setups is very high. Similarly, there is
an absence of standard protocols for large-scale production of the devices. Thus, it is imperative to
come up with robust and transversal manufacturing protocols that facilitate bulk fabrication of cheap,
reusable and easy to dispose components [46,124]. Secondly, the conservatism and reluctance of the
pharmaceutical industry. This is a business that owing to its strict regulatory requirements, relies
heavily on traditional manufacturing approaches. There would have to be a substantial cost reduction
or operational advantage to encourage the use of microfluidic technology beyond the laboratory
scale [18]. In this context, direct collaboration between companies and researchers from different fields
should be fostered, in order to truly understand the needs of the industry and adapt the designing
processes accordingly [46]. Adopting 3D printing as the main strategy for producing microfluidic chips
could also help in this regard, since this technique is low-cost, easy to use, efficient and allows for rapid
prototyping and quick translation of new designs [18]. Lastly, broad acceptance by the general public
is a major challenge. Costumers would need to be reassured that quality control standards would
still be met, and that the final pharmaceutical product was produced in compliance with regulatory
practices [18]. Nonetheless, the use of microfluidics is paving the way to revolutionize the landscape
of pharmaceutics, and it is envisioned that with continued progress, it will be possible to bridge the
gap between the lab and the clinic [8].
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